On September 19, 2023, it was reported that the Collective Family Office LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter. According to the company’s filing with the Securities and Exchange Commission (SEC), they purchased 305 shares of the biopharmaceutical company’s stock, which were valued at approximately $219,000.
Regeneron Pharmaceuticals is a renowned player in the biopharmaceutical industry, known for its innovative research and development efforts. The company has been involved in groundbreaking discoveries and advancements in healthcare. As such, it has garnered interest from investors seeking to be part of its growth trajectory.
Shares of NASDAQ REGN opened at $824.51 on Tuesday, indicating positive market sentiment towards the company. Over recent months, REGN has demonstrated stability in its stock price with a fifty-day moving average price of $784.26 and a two hundred-day moving average price of $774.72.
Having a current ratio of 5.45 and a quick ratio of 4.64 indicates that Regeneron Pharmaceuticals maintains good liquidity and can meet its short-term obligations efficiently. Additionally, with a debt-to-equity ratio of 0.11, the company appears to have sound financial management practices.
Regeneron Pharmaceuticals’ impressive performance is further exemplified by its market capitalization of $89.51 billion as of this date—an indication of its significant presence in the industry. The company’s strong position has also attracted attention from investors who see value in investing their capital here.
With a price-to-earnings (P/E) ratio of 21.80 and a P/E growth ratio (P/E/G) of 2.45, Regeneron Pharmaceuticals stands out as an attractive investment opportunity for those seeking stable returns over time while accounting for future growth potential. A beta value of 0.19 suggests that the stock is less volatile compared to the overall market, which could be appealing to risk-averse investors.
Investors and stakeholders in the biopharmaceutical industry are keeping a close eye on Regeneron Pharmaceuticals as it continues to innovate and develop novel treatments. As this report highlights, Collective Family Office LLC recognized the potential in investing in Regeneron Pharmaceuticals by acquiring a stake. This move not only reflects confidence in the company’s growth prospects but also demonstrates the financial acumen of Collective Family Office LLC itself.
In conclusion, the acquisition of a new stake by Collective Family Office LLC underscores the interest and confidence from investors in Regeneron Pharmaceuticals. The company’s strong financials, stable stock performance, and notable contributions to healthcare innovation have made it an attractive prospect for various investment portfolios. With its continued advancements and commitment to driving progress in biopharmaceutical development, Regeneron Pharmaceuticals is poised for continued success in the foreseeable future.
Updated on: 05/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
1:00 PM (UTC)
Date:05 December, 2023
|Analyst / firm||Rating|
Michael Walkley Walkley
Institutional Investors Show Strong Confidence in Regeneron Pharmaceuticals as Company Achieves Impressive Financial Performance
Regeneron Pharmaceuticals, a biopharmaceutical company listed on NASDAQ under the symbol REGN, has recently seen changes in its positions and holdings by various institutional investors and hedge funds. This includes NewSquare Capital LLC, which increased its holdings in Regeneron Pharmaceuticals by an astonishing 1,450.0% in the first quarter of this year. With an additional purchase of 29 shares, NewSquare now owns 31 shares of Regeneron’s stock valued at $25,000.
Sunbelt Securities Inc., another institutional investor, also entered a new position with Regeneron Pharmaceuticals earlier this year. Their purchase, valued at approximately $25,000, reflects their confidence in the potential growth of the company.
Steward Financial Group LLC joined the list of institutional investors adding to their ownership in Regeneron Pharmaceuticals during the fourth quarter of last year. The company purchased a new position valued at about $28,000.
Furthermore, Householder Group Estate & Retirement Specialist LLC decided to join the group of investors taking positions in Regeneron Pharmaceuticals during the first quarter. They acquired an additional 35 shares and currently own 37 shares worth $30,000.
Lastly, Manchester Capital Management LLC also saw potential in Regeneron Pharmaceuticals and boosted its position by a staggering 740.0% during the first quarter. Their holdings now amount to 42 shares valued at $35,000.
These moves by various institutional investors and hedge funds showcase their belief in the future prospects of Regeneron Pharmaceuticals. As a result, such investments contributed to an overall ownership percentage of 84.15% from these entities alone.
In other news related to Regeneron Pharmaceuticals’ financials and performance indicators, CFO Robert E. Landry recently sold 223 shares on Wednesday, August 23rd. The transaction was completed at an average price per share of $844.00 for a total transaction value of $188,212.00. Following the sale, Landry now owns 31,699 shares valued at approximately $26,753,956.
Adding to this, EVP Plew Daniel P. Van also sold 6,197 shares of Regeneron Pharmaceuticals stock on Thursday, August 24th. The average price per share for this transaction was $841.71, resulting in a total transaction value of $5,216,076.87. Van now owns 21,508 shares in the company with an approximate valuation of $18,103,498.
These transactions were duly disclosed by Regeneron Pharmaceuticals in documents filed with the Securities and Exchange Commission (SEC). For more information pertaining to these sales and further details regarding the company’s financials, interested individuals can visit the SEC website.
In terms of financial performance metrics, Regeneron Pharmaceuticals announced its earnings results for the most recent quarter on Thursday, August 3rd. The biopharmaceutical company reported an impressive EPS (earnings per share) of $10.24 for the quarter – surpassing the consensus estimate of $8.48 by a substantial margin of $1.76.
Additionally, Regeneron Pharmaceuticals recorded revenue of $3.16 billion for the quarter compared to a consensus estimate of $3.02 billion. This represents a year-over-year increase of 10.5% in revenue growth for the company.
The return on equity (ROE) for Regeneron Pharmaceuticals stood at an impressive 19.19%, while boasting a net margin of 33.93%. These figures collectively indicate robust financial performance during this period when compared to previous years.
Looking ahead to future earnings projections and estimates made by research analysts covering Regeneron Pharmaceuticals stock suggest that it is expected to post an EPS of 35.42 for this fiscal year.
Several equity research analysts have recently provided their insights and recommendations on REGN stock. Argus, for example, boosted the price target on shares of Regeneron Pharmaceuticals from $825.00 to $920.00 and issued a “buy” rating for the stock.
Canaccord Genuity Group also raised their rating for Regeneron Pharmaceuticals from “hold” to “buy”, and increased their price target from $720.00 to $992.00 in a report published on Monday, August 21st.
BMO Capital Markets joined this group of bullish analysts by elevating their price objective on shares of Regeneron Pharmaceuticals from $960.00 to $985.00 with an “outperform” rating.
In conclusion, institutional investors and hedge funds have demonstrated notable interest in Regeneron Pharmaceuticals through significant increases in their positions over the past few quarters. Meanwhile, company insiders have also been active participants in selling their shares, albeit at considerably higher valuations than their original purchase prices.
With notable revenue growth and solid financial performance reported for the most recent quarter, coupled with favorable ratings and price targets from various research analysts, it appears that Regeneron Pharmaceuticals is poised for continued success in the biopharmaceutical industry moving forward.